Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.55 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.55 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.55 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.55 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.55 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.55 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.43 |
| ▸ | HPGD | P15428 | 6/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.39 |
| ▸ | TUBB | P07437 | 4/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL829516 | 0.85 | ALDH1A1 (0.55) | ALDH1A1HPGDCYP1A2XBP1CYP2C19 | |
| SCHEMBL829884 | 0.84 | GAA (0.49) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL828877 | 0.84 | ALDH1A1 (0.48) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL388750 | 0.83 | MEN1 (0.48) | GABRA1GABRA3ALDH1A1HPGDCYP1A2 | |
| SCHEMBL12890683 | 0.83 | ALDH1A1 (0.47) | ALDH1A1HPGDCYP1A2XBP1CYP2C19 | |
| SCHEMBL383862 | 0.83 | ALDH1A1 (0.64) | ALDH1A1HPGDCYP1A2XBP1CYP2C19 | |
| SCHEMBL832047 | 0.81 | ALDH1A1 (0.48) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL862239 | 0.80 | ALDH1A1 (0.52) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL832595 | 0.80 | ALDH1A1 (0.48) | ALDH1A1HPGDCYP1A2XBP1CYP2C19 | |
| SCHEMBL386125 | 0.80 | ALDH1A1 (0.51) | ALDH1A1HPGDCYP1A2XBP1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197842-B1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORP (US) | 2012-05-23 | — | — | EP | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| EP-2197842-A1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009032116-A1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | GABRA1 4029/4885GABRA5 3618/4885GABRG2 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.